Related Articles
Interim 18F‑FDG PET/CT improves the prognostic value of S‑IPI, R‑IPI and NCCN‑IPI in patients with diffuse large B‑cell lymphoma
Diffuse large B-cell lymphoma: 10 years' real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone
Reassessment of the prognostic value of the International Prognostic Index and the revised International Prognostic Index in patients with diffuse large B-cell lymphoma: A multicentre study
miR‑150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B‑cell lymphoma
A modified prognostic model in patients with diffuse large B‑cell lymphoma treated with immunochemotherapy